Quest Diagnostics Incorporated (DGX)

Over the past six months, Quest Diagnostics' stock has experienced a gain of approximately 2%, and over the past 52 weeks, the stock has increased by 17%, outperforming the Health Care ETF. The stock's 52-week high was $197.55, reached in October 2025, and its 52-week low was $148.76. As of December 5, 2025, the closing price was $182.51. On October 21, 2025, DGX reported its third-quarter results for 2025, with net revenues increasing 13.1% year-over-year to $2.82 billion, and adjusted EPS rose by 13% year-over-year to $2.60. A recent event includes the completion of a lab joint venture transaction with Corewell Health.

Demand for Quest Diagnostics' products and services has seen a pickup as more individuals return to the healthcare system for regular care after delays during the pandemic. The company has also observed "breakout" growth in direct-to-consumer (DTC) testing, a trend accelerated by the COVID-19 pandemic and a broader shift towards telehealth and e-commerce.

Quest Diagnostics, Inc. is a leading American clinical laboratory and provider of diagnostic information services operating within the Healthcare sector. They offer a comprehensive portfolio of clinical testing, anatomic pathology testing, molecular diagnostics, and clinical chemistry, providing diagnostic insights for various conditions. The company offers COVID-19 testing services and has expanded into consumer-initiated testing through QuestDirect. They also manage hospital outreach laboratories and provide services under various brands, with recent innovations in oncology, brain health, and women's health.

Quest Diagnostics has a significant global presence with its headquarters in Secaucus, New Jersey. It operates extensively across the United States, with approximately 6,188 clinics as of January 2026, and has operations in Puerto Rico, Mexico, Brazil, India, and Ireland. Its products and services are utilized by customers on six continents and in over 130 countries, with sales and marketing support provided to international clients in more than 50 countries worldwide.

Quest Diagnostics has maintained a strong brand reputation, being named one of FORTUNE's World's Most Admired Companies for the 11th consecutive year in 2025. In the "Health Care: Pharmacy and Other Services" industry category, Quest ranked number three in 2025 and scored high marks in areas such as quality of management, long-term investment, and people management. In 2018, Quest Diagnostics was linked to inaccuracies in over 200 women's cervical smear tests for Ireland's national screening program.

Quest Diagnostics Incorporated is predominantly owned by institutional investors, who hold approximately 94.13% of the shares. Vanguard Group Inc. is the largest individual institutional shareholder, owning 14.25 million shares, representing 12.81% of the company. Company insiders hold a smaller but significant stake of 1.77%, and retail investors own 4.10%. Insiders have been net sellers in the last quarter.